Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALBO Albireo Pharma	$44.15	$44.17	$16.02 ▼ $45.23	$913.91M	1.03	704,539 shs	1.24 million shs
ALDX Aldeyra Therapeutics	$3.05 -3.8%	$2.45	$1.14 ▼ $7.20	$182.68M	0.68	826,542 shs	801,493 shs
FHTX Foghorn Therapeutics	$4.72 -0.6%	$4.25	$2.94 ▼ $10.25	$263.10M	3.04	143,149 shs	162,682 shs
KALV KalVista Pharmaceuticals	$12.15 -1.3%	$12.50	$7.30 ▼ $15.50	$604.05M	-0.01	465,919 shs	1.36 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALBO Albireo Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
ALDX Aldeyra Therapeutics	0.00%	+9.71%	+35.56%	-53.65%	-15.98%
FHTX Foghorn Therapeutics	0.00%	+9.26%	+14.01%	+16.54%	-9.75%
KALV KalVista Pharmaceuticals	0.00%	-6.25%	+6.39%	+2.19%	+6.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALBO Albireo Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALDX Aldeyra Therapeutics	2.8146 of 5 stars	3.5	3.0	0.0	0.0	2.9	1.7	0.6
FHTX Foghorn Therapeutics	1.7066 of 5 stars	3.6	2.0	0.0	0.0	0.0	1.7	0.6
KALV KalVista Pharmaceuticals	3.8292 of 5 stars	3.6	0.0	0.0	4.4	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALBO Albireo Pharma	0.00	N/A	N/A	N/A
ALDX Aldeyra Therapeutics	3.00	Buy	$9.50	211.48% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	156.89% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	104.39% Upside

Current Analyst Ratings Breakdown

Latest KALV, ALBO, ALDX, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$9.00
4/23/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00
4/8/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/7/2025	ALDX Aldeyra Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $9.00
4/4/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALBO Albireo Pharma	$40.58M	22.52	N/A	N/A	$9.11 per share	4.85
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$1.19 per share	N/A
FHTX Foghorn Therapeutics	$22.60M	11.64	N/A	N/A	($0.82) per share	-5.76
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALBO Albireo Pharma	-$34.03M	-$6.72	N/A	N/A	N/A	-228.51%	-97.13%	-46.89%	N/A
ALDX Aldeyra Therapeutics	-$55.85M	-$0.97	N/A	N/A	N/A	N/A	-72.58%	-52.32%	7/30/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-104.25%	-78.69%	7/10/2025 (Estimated)

Latest KALV, ALBO, ALDX, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ALDX Aldeyra Therapeutics	-$0.25	-$0.17	+$0.08	-$0.17	($0.80) million	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALBO Albireo Pharma	N/A	N/A	N/A	N/A	N/A
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALBO Albireo Pharma	N/A	6.32	6.23
ALDX Aldeyra Therapeutics	0.24	6.49	6.49
FHTX Foghorn Therapeutics	N/A	3.16	3.16
KALV KalVista Pharmaceuticals	N/A	10.44	10.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALBO Albireo Pharma	94.25%
ALDX Aldeyra Therapeutics	59.71%
FHTX Foghorn Therapeutics	61.55%
KALV KalVista Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ALBO Albireo Pharma	6.90%
ALDX Aldeyra Therapeutics	9.60%
FHTX Foghorn Therapeutics	7.58%
KALV KalVista Pharmaceuticals	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALBO Albireo Pharma	130	20.70 million	19.27 million	Optionable
ALDX Aldeyra Therapeutics	15	59.90 million	54.15 million	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.50 million	Optionable

KALV, ALBO, ALDX, and FHTX Headlines

Recent News About These Companies

How KalVista Pharma Is Taking On A Rare But Deadly Disease

June 20 at 10:06 AM | msn.com

FDA delays decision on hereditary disease drug

June 18, 2025 | beckershospitalreview.com

KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down - What's Next?

June 16, 2025 | marketbeat.com

Makary Considers More Cuts at FDA Amid Continued Delays

June 16, 2025 | biospace.com

FDA Plans to Shrink; Nursing Shortage at Walter Reed; Pelvic Floor Therapy for Men?

June 16, 2025 | medpagetoday.com

DOGE cuts cause FDA to delay decision on hereditary disease drug

June 16, 2025 | msn.com

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

June 16, 2025 | biopharmadive.com

KalVista Pharmaceuticals Shares Edge Down on FDA Delays for Sebetralstat Application

June 16, 2025 | marketwatch.com

FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision

June 16, 2025 | fiercebiotech.com

FDA won’t meet PDUFA goal date for sebetralstat

June 14, 2025 | thepharmaletter.com

FDA Tells Drugmaker ‘Heavy Workload’ to Delay Approval Decision

June 13, 2025 | bloomberg.com

DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals’ Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints

June 13, 2025 | cantechletter.com

KalVista said FDA will not meet review date for sebetralstat

June 13, 2025 | msn.com

Health Sector Updates: Breakthroughs and Challenges

June 13, 2025 | devdiscourse.com

KalVista Pharmaceuticals Hit by FDA Delays

June 13, 2025 | marketwatch.com

US FDA extends review of KalVista's swelling disorder drug due to heavy workload

June 13, 2025 | reuters.com

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

June 13, 2025 | businesswire.com

Research Analysts Issue Forecasts for KALV FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Cantor Fitzgerald Comments on KALV FY2026 Earnings

June 11, 2025 | marketbeat.com

Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells 7,169 Shares of Stock

June 11, 2025 | insidertrades.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 7,169 Shares

June 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV, ALBO, ALDX, and FHTX Company Descriptions

Albireo Pharma NASDAQ:ALBO

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Aldeyra Therapeutics NASDAQ:ALDX

$3.05 -0.12 (-3.79%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.06 +0.01 (+0.33%)

As of 06/20/2025 07:34 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Foghorn Therapeutics NASDAQ:FHTX

$4.72 -0.03 (-0.63%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.70 -0.01 (-0.32%)

As of 06/20/2025 04:11 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

KalVista Pharmaceuticals NASDAQ:KALV

$12.15 -0.16 (-1.30%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$12.56 +0.41 (+3.37%)

As of 06/20/2025 07:15 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time